Shire continues to beat expectations
This article was originally published in Scrip
Shire's third quarter figures saw it continue to cash in on Genzyme's manufacturing woes, and reap the reward of getting into the rare disease space well ahead of big pharma's recent surge of interest.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.